Physician profile
James A Watson
NPI 1548280506
$4,349.76
in general payments reported to CMS, 2019-2025
24 companies · $783 in 2025
The $783 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.68 · 2022: $113 · 2023: $2,090 · 2024: $1,351 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $988.64 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $514.51 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $505.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $286.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $277.46 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.93 | 2023-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $218.95 | 2023-2024 | Closurefast, Intellis Adaptivestim, Venaseal |
| Exact Sciences Corporation | $217.70 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $204.52 | 2022-2025 | |
| Pfizer INC. | $188.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $177.24 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Corcept Therapeutics | $80.25 | 2023-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $60.44 | 2024 | Spravato |
| Astellas Pharma US INC | $43.08 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $41.43 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $40.48 | 2023 | Quviviq |
| Dexcom, INC. | $40.03 | 2023-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $37.91 | 2022 | |
| Merck Sharp & Dohme LLC | $33.26 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Daiichi Sankyo INC. | $26.65 | 2023 | Injectafer |
| Irhythm Technologies, INC. | $17.53 | 2024 | Zio Xt Patch, Zio Monitor |
| Currax Pharmaceuticals LLC | $17.05 | 2025 | Contrave |
| Amgen INC. | $13.48 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.